Gsk (GLAXF) Return on Capital Employed (2009 - 2026)

Gsk's Return on Capital Employed history runs 18 years deep, the most recent figure standing at 9.49% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 59.0% year-over-year to 9.49%; the TTM figure through Mar 2026 stood at 9.49% (up 59.0% YoY), while the FY2025 annual figure was 9.82%, down 112.0% from the prior year.
• Return on Capital Employed was 9.49% for Q1 2026 at Gsk, roughly flat from 9.46% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 26.36% in Q4 2023 to a low of 5.23% in Q2 2022.
• Historically, Return on Capital Employed has averaged 11.68% across 5 years, with a median of 9.63% in 2023.
• The sharpest annual moves came in 2022 and 2024: Return on Capital Employed soared 1429 bps in 2022, then tumbled 920 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 22.24% in 2022, then climbed by 19 bps to 26.36% in 2023, then tumbled by 35 bps to 17.15% in 2024, then plunged by 45 bps to 9.46% in 2025, then gained by 0 bps to 9.49% in 2026.
• The last three Return on Capital Employed figures came in at 9.49% (Q1 2026), 9.46% (Q4 2025), and 11.86% (Q3 2025), per Business Quant data.